Picture ConsulTech GmbH GDPR-compliant E-Col Cloud Document Management 650x80px
Document › Details

Alligator Bioscience AB. (12/17/19). "Press Release: First Patient Dosed with ATOR-1017 Developed for Metastasized Cancer". Lund.

Region Region Sweden
Organisation Organisation Alligator Bioscience AB (Nasdaq Stockholm: ATORX)
  Group Alligator Bioscience (Group)
Product Product  phase 1 study
Persons Person Norlén, Per (Alligator Bioscience 201606 CEO)
  Person 2 Hofvander, Cecilia (Alligator Bioscience 201801 Director IR + Communications)

Alligator Bioscience (Nasdaq Stockholm: ATORX), today announced that the first patient has been successfully dosed in the Phase I study with the wholly owned 4-1BB antibody ATOR-1017, which is being developed for the treatment of metastasized cancer.

The Phase I study is a dose escalation study in patients with advanced cancer and this is the first time ATOR-1017 is being evaluated in humans. The study will be conducted at three different clinics in Sweden and include up to 50 patients. The primary objective of the study is to assess the safety and tolerability of ATOR-1017 and to determine the recommended dose for the subsequent Phase II studies.

ATOR-1017 activates 4-1BB receptors which increases the ability of the immune system to detect and kill tumor cells. This makes 4-1BB a particularly attractive target for cancer immunotherapy. ATOR-1017 has a unique profile related to the fact that its immune-stimulatory function is stronger in areas where immune cells are abundant, notably in tumors. This creates an opportunity for a strong immune activation that can increase efficacy and reduce side effects for the patient.

“In the preclinical studies, ATOR-1017 has showed a strong and long-lasting immune response, and even created immunity to cancer, while minimizing the side effects through tumor-directed immune activation. This profile puts ATOR-1017 at the forefront of the field and it will be very exciting to follow the continued clinical development “, said Per Norlén, CEO of Alligator Bioscience.

For further information, please contact:
Cecilia Hofvander, Director Investor Relations & Communications
Phone +46 46 540 82 06

The information was submitted for publication, through the agency of the contact persons set out above, at 1:00 p.m. CET on December 17, 2019.

About Alligator Bioscience

Alligator Bioscience AB is a clinical-stage biotechnology company developing tumor-directed immuno-oncology antibody drugs. Alligator’s growing pipeline includes six lead clinical and preclinical drug candidates: mitazalimab (ADC-1013), ATOR-1015, ATOR-1017, ALG.APV-527 (co-developed with Aptevo Therapeutics Inc.), ATOR-1144 and AC101 (in clinical development by Shanghai Henlius Biotech Inc.). Alligator’s shares are listed on Nasdaq Stockholm (ATORX). The Company is headquartered in Lund, Sweden, and has approximately 55 employees. For more information, please visit

Record changed: 2020-03-15


Picture ConsulTech GmbH RnD Credit Germany 650x80px

More documents for Alligator Bioscience (Group)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]


Picture EBD Group BioTech Showcase 2021 Whitepaper Presenting 650x80

» top